Durham public company begins furloughs as it searches for capital


A drug developer in Durham has furloughed about half its workforce as it searches for additional capital.

Previous Riordan Clinic adds new chief medical officer with background in agriculture
Next Gaithersburg’s Vector BioMed appoints FDA alum Jakob Reiser to executive team